Skip to content

The effects of repetitive transcranial magnetic stimulation in patients with nonalcoholic fatty liver disease: a randomized controlled trial

A randomized controlled trial of the efficacy of repetitive transcranial magnetic stimulation in the treatment of patients with nonalcoholic fatty liver disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065591
Enrollment
Unknown
Registered
2022-11-09
Start date
2022-11-30
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

Sponsors

the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18-60 years old, BMI >= 24kg/m2, regardless of gender and nationality, right-handed; 2. NAFLD patients diagnosed by MRI-PDFF before randomization; 3. alcohol intake of women is less than 10g/day, and alcohol intake of men is less than 20g/day; 4. No TMS stimulation treatment before; 5. Willing to sign the informed consent form, understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial protocol to complete this trial 6. Weight stability (± 5%) must be reported for 3 months before participating in the study

Exclusion criteria

Exclusion criteria: 1. Head injury or epilepsy; 2. Metal implants ;Pacemakers and any other contraindications to MRI or rTMS; 3. Weight fluctuation>5% within 3 months; 4. Currently suffering from mental illness or taking antipsychotic drugs; 5. People who use diet pills or very low-calorie diet recently; 6. Eating disorders or material dependence; 7. Presence of diabetes or unstable cardiovascular disease; 8. Pregnant or breast fed; 9. Brain MRI showed abnormal results.

Design outcomes

Primary

MeasureTime frame
MRI-PDFF;Fibroscan;body weight;

Secondary

MeasureTime frame
Body Mass Index;waist circumference;lipid metabolism;liver function;HOMA-IR;energy intake;Food craving;brain network activity;

Countries

China

Contacts

Public ContactQiuling Zhang

the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

nfmkzql@163.com+86 13867485066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026